Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Core Viewpoint - Relmada Therapeutics, Inc. has announced a PIPE financing expected to generate approximately $160 million in gross proceeds to support its research and development efforts in oncology and central nervous system therapies [1][3]. Group 1: PIPE Financing Details - The PIPE financing involves the sale of 29,474,569 shares of common stock at a price of $4.75 per share and pre-funded warrants for 4,210,527 shares at a price of $4.749 per warrant, with an exercise price of $0.001 per share [2]. - The financing is anticipated to close around March 11, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the PIPE financing will be utilized for working capital and general corporate purposes, including advancing the research and development of the company's product candidates [3]. Group 3: Company Overview - Relmada is a clinical-stage biotechnology company focused on developing innovative therapies for oncology and central nervous system conditions, with lead candidates NDV-01 and sepranolone in mid-stage clinical development [6].